|
ÆÊÄ¿³ØÆà |
[Global CRO] CTM (Global study)
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
8³â¡è |
04.30 |
03.04 |
|
|
ÆÊÄ¿³ØÆà |
[±Û·Î¹úCRO] CRA~SCRA (ÄÚ¾î/µ¥µðÆÀ)
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
04.30 |
03.04 |
|
|
ÆÊÄ¿³ØÆà |
[±¹³»Á¦¾à»ç] ÀÓ»óPM
¼¿ï ÀüÁö¿ª, °æ±â ¼º³²½Ã ºÐ´ç±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
04.30 |
03.04 |
|
|
ÇÁ·ÎÇÚÁîÄÚ¸®¾Æ |
´ëÇüÁ¦¾à»ç M,W(´ë¸®~°úÂ÷Àå±Þ-2³âÀÌ»ó)
°æ±â ¼º³²½Ã ¼öÁ¤±¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
02.27 |
|
|
HRKorea |
º¸Åø¸®´® Åå½Å PM(Product Manager) - º¸Åø¸®´® Åå½Å ÇÁ¸®¸¶
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
12.31 |
02.19 |
|
|
JYpartners |
ÀÓ»ó´ã´çÀÚ(Ã¥ÀÓ~¼ö¼®)
°æ±â ¼º³²½Ã ºÐ´ç±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
13³â¡è |
ä¿ë½Ã |
01.22 |
|
|
ÇÁ·ÎÇÚÁîÄÚ¸®¾Æ |
À¯¸í¹ÙÀÌ¿ÀÁ¦¾à»ç ÀÓ»óÆÀÀå(°úÂ÷Àå±Þ)
°æ±â ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
10³â¡è |
ä¿ë½Ã |
11.07 |
|
|
HRKorea |
Biometrics ´ã´çÀÚ Ã¤¿ë - ÀÓ»ó°³¹ß Àü·« ±âȹ, CRO °ü¸® °¨
¼¿ï ÀüÁö¿ª | ´ëÇпø(¼®»ç) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
3³â¡è |
07.31 |
11.07 |
|
|
HRKorea |
CPM (Clinical Project Manager) ´ã´çÀÚ Ã¤¿ë - ÀÓ»ó °³¹ß
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
3³â¡è |
07.31 |
11.07 |
|
|
HRKorea |
PV(Pharmacovigilance) ´ã´çÀÚ Ã¤¿ë - ÀÓ»ó½ÃÇè SAE Handlin
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
07.31 |
11.07 |
|
|
¿¡ÀÌÄ¡¾ËÄÁ¼³Æà |
📌 cra, PM, crm, ÀÓ»óÆÀÀå/ÀÓ¿ø, SSUÆÀÀå ÀçÅñîÁö~
Àü±¹ ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
»ó½Ãä¿ë |
10.26 |
|
|
ÇÁ·ÎÇÚÁîÄÚ¸®¾Æ |
´ëÇüÁ¦¾à»ç CRÆÀÀå
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
10³â¡è |
ä¿ë½Ã |
10.10 |
|
|
ÇÁ·ÎÇÚÁîÄÚ¸®¾Æ |
´ëÇüÁ¦¾à»ç PMS PM(ÆÄÆ®Àå-´ë¸®±ÞÀÌ»ó)1¸í/ÆÀ¿ø 2¸í(»ç¿ø~ÁÖ
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
09.28 |
|
|
ÇÁ·ÎÇÚÁîÄÚ¸®¾Æ |
»óÀåÁ¦¾à»ç ÀÓ»óÆÀ(7³âÀÌ»ó)
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
7³â¡è |
ä¿ë½Ã |
09.28 |
|
|
ÇÁ·ÎÇÚÁîÄÚ¸®¾Æ |
»óÀåÁ¦¾à»ç ÀÓ»ó°³¹ß(7³âÀÌ»ó)-ASAP
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
7³â¡è |
ä¿ë½Ã |
08.30 |
|